ArticleBiomedical journal2026
qHBsAg outperforms ALT/qHBsAg ratio in predicting HBsAg seroclearance after cessation of entecavir versus tenofovir.
Article in Biomedical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe aimed to establish the optimal value of the alanine aminotransferase (ALT)/quantitative HBsAg (qHBsAg) ratio and qHBsAg level at end of treatment (EOT) to predict HBsAg seroclearance following cessation of entecavir versus tenofovir disoproxil fumarate (TDF) in HBeAg-negative with chronic hepatitis B (CHB) patients. MATERIAL AND
methodsThis retrospective cohort study included 715 HBeAg-negative patients without cirrhosis who had previously received entecavir (n = 438) or TDF (n = 277).
resultsThe cumulative incidences of HBsAg seroclearance at 5 and 10 years after cessation of entecavir or TDF were 13.0 % and 33.8 %, respectively. Both a qHBsAg level <100 IU/mL and an ALT/qHBsAg ratio ≥0.2 at EOT were independent predictors of HBsAg seroclearance (p < 0.001). A qHBsAg of 100 IU/mL had significantly lower Akaike information criterion (AIC) and Bayesian information criterion (BIC) values than an ALT/qHBsAg ratio of 0.2 at EOT (AIC: 1273 vs. 1305, BIC: 1276 vs. 1308, both p < 0.001). Additionally, patients who discontinued entecavir therapy had a higher rate of HBsAg seroclearance than patients who discontinued TDF therapy, regardless of qHBsAg ≥100 IU/mL (p = 0.027) or ALT/qHBsAg ratio <0.2 (p = 0.028). The optimal values for predicting HBsAg seroclearance were 300 and 100 IU/mL for qHBsAg and 0.1 and 0.2 for the ALT/qHBsAg ratio after stopping entecavir versus TDF, respectively.
conclusionsA qHBsAg level <100 IU/mL at EOT is better predictor of HBsAg seroclearance than an ALT/qHBsAg ratio ≥0.2. Compared to TDF, entecavir was associated with higher rates of HBsAg seroclearance in patients with higher qHBsAg level or a lower ALT/qHBsAg ratio at EOT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.